Vertex Pharmaceuticals Appoints Former Boston Scientific CFO Daniel Brennan to Board

Executive Summary

On October 20, 2026, Vertex Pharmaceuticals Incorporated filed a Current Report on Form 8-K under Item 5.02 announcing the election of Daniel Brennan to its Board of Directors, expanding board membership from ten to eleven. Mr. Brennan will serve as a member of the Audit and Finance Committee.

Key Details & Director Background

• Professional Background: Mr. Brennan served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation from January 2014 until his retirement in June 2025, having previously served as Senior Vice President, Corporate Controller from 2010 through 2013 and holding various finance leadership positions dating back to 1996.
• Other Directorships: Currently sits on the boards of Waters Corporation (since November 2022) and Madrigal Pharmaceuticals (since August 2025). Previously served on Nuance Communications' board until its acquisition by Microsoft in March 2022.
• Credentials: Certified Public Accountant with a B.S. in Finance and Investments and an M.B.A. from Babson College.

Compensation Arrangements

• Initial Equity Award: In connection with his appointment on October 20, 2026, Mr. Brennan received a $400,000 restricted stock unit (RSU) award scheduled to vest in October 2027.
• Related Party Disclosures: No transactions between Vertex and Mr. Brennan requiring disclosure under Item 404(a) of Regulation S-K were reported.

Market & Trading Significance

This is a standard governance update reflecting the addition of deep financial and medical technology expertise to Vertex's board and Audit and Finance Committee. It carries low direct impact on short-term stock trading.